ANDA 205550, held by Jubilant Generics. Darifenacin Hydrobromide.
As of Nov 16, 2026, ANDA 205550 (Darifenacin Hydrobromide), held by Jubilant Generics, was first approved by FDA on Oct 12, 2016, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 12, 2016 | Original application | Approved | None posted |
| Darifenacin HydrobromideEQ 7.5MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Discontinued |
| Darifenacin HydrobromideEQ 15MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters